Can-Fite BioPharma Ltd. (CANF) Form 6-K — Jul 1, 2026
Can-Fite BioPharma announced that its Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated durable overall survival outcomes. The open-label study enrolled 20 patients who had progressed following standard therapies, with Namodenoson being well tolerated and showing a safety profile consistent with prior clinical trials. Updated survival analysis in the third-line population showed median overall survival exceeded 5 months, with 62.5% of patients surviving five months or longer and 37.5% surviving seven months or longer.
Key figures
- Longest survival
- > 18 months
- Patients enrolled
- 20
- Third line patients
- 14
- Fourth line patients
- 1
- Second line patients
- 5
- Survival greater than 5 months
- 62.5%
- Survival greater than 7 months
- 37.5%
- Median overall survival third line
- > 5 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.